Committee for Medicinal Products for Human Use
- Health
CHMP issues positive opinion for Jardiance® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fraction
Ingelheim, Germany: – The positive opinion is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in…
Read More » - Health
Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age
Ingelheim, Germany: No approved therapy for the treatment and prevention of venous thromboembolic events in children until now Current standard…
Read More »